Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury

• Sponsor: Children's Medical Center Dallas (Other)
• Overall Status: Completed
• CT.gov ID: NCT02010034
• Collaborator: (none)
• Enrollment: 15
• Location: 1
• Arm: 1
• Duration (Months): 66.2
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

This study is being done to determine if an investigational study drug called Omegaven can help to improve liver disease thought to be caused by Total Parenteral Nutrition (TPN). TPN is intravenous feeding (IV feeding tube) that provides patients the nutrients when they are unable to drink fluid or eat food by mouth.

Condition or Disease	Intervention/Treatment	Phase
Liver Disease; Impaired Liver Function; Parenteral Nutrition Associated Liver Disease	Drug: Omegaven	N/A

Detailed Description

PAtients with direct bilirubin >2gm/dL and short bowel syndrome are eligible for enrollment. Omegaven at 1gm/kg/day will be administered via central venous line instead of standard lipid preparations.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 15 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Supportive Care
• Official Title: Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury
• Study Start Date: Aug 1, 2013
• Actual Primary Completion Date: Feb 5, 2019
• Actual Study Completion Date: Feb 5, 2019

Arms and Interventions

Arm	Intervention/Treatment
Other: Compassionate use This lipid preparation is only being used for compassionate use.	Drug: Omegaven; Omegaven will be used in place of soy oil Intralipid

Outcome Measures

Primary Outcome Measures

1. Bilirubin in mg/dL [12 weeks]

   PN associated liver disease can be reversed or its progression halted by using a parenteral fat emulsion prepared from fish oil as measured by normalization of serum levels of hepatic enzymes and bilirubin 1. after reaching bilirubin levels >2mg/dl, subjects receiving Omegaven will reach a bilirubin level < 2mg/dL faster that patients receiving conventional fat emulsions.

Secondary Outcome Measures

1. Number of participants with adverse events [12 weeks]

   a. After starting Omegaven on PN, the rate of fatty acid deficiencies and imbalances will be as low as before Omegaven. Also, the rate of triglyceride events >400mg/dL with Omegaven will be similar to that seen with PN administration with soy oil Intralipid. B. PN containing Omegaven will be safe for patients with respect to the risk of unexpected bleeding, coagulopathies, and other adverse events.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 2 Months to 10 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Patients must be 2 months -10 years of age

2. Patients who are PN dependent (unable to meet nutritional needs solely by enteral nutrition) and are expected to require PN for at least another 30 days

3. Patients considered eligible for study participation must have parenteral nutrition associated liver disease (PNALD) as defined by a direct bilirubin of >2.0mg/dL. Other causes of liver disease should be excluded. A liver biopsy is not necessary for treatment

4. 2 consecutive direct bilirubin test results >2.0mg/dl

5. The patient must have failed standard therapies to prevent the progression of liver disease such as surgical treatment, cyclic TPN, avoiding overfeeding, reduction/removal of copper and manganese from TPN, advancement of enteral feeding, and use of ursodiol (Actigall)

6. Subjects who are currently under treatment for PNALD with Compassionate Use Omegaven and have a direct Bilirubin of< 2, but who remain TPN dependent and require continued therapy with Omegaven

Exclusion Criteria:

1. Other known causes of chronic liver disease (hepatitis C, cystic fibrosis, biliary atresia and alpha 1 anti-trypsin deficiency)

2. Enrollment in any other clinical trial involving an investigational agent (unless approved by the designated physicians on the multidisciplinary team)

3. The parent, guardian, or child is unwilling to provide consent or assent

4. Allergy to any fish product, egg protein, and/or previous allergy to Omegaven

5. Active coagulopathies characterized by on-going bleeding or by a requirement for clotting factor replacement such as fresh frozen plasma or cryoprecipitate to maintain homeostasis

6. Impaired lipid metabolism or severe hyperlipidemia with or without pancreatitis

7. Unstable diabetes mellitus

8. Stroke/embolism

9. Collapse and shock

10. Undefined coma status

11. Active infection at time of initiation of Omegaven® up until such time as child is afebrile with stable vital signs and one negative 48 hour culture

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Children's Medical Center of Dallas	Dallas	Texas	United States	75235

Sponsors and Collaborators

• Children's Medical Center Dallas

Investigators

• Principal Investigator: Nandini Channabasappa, MD, Childrens Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Nandini Channabasappa, MD, Director, Intestinal Rehabilitation Program, Children's Medical Center Dallas
• ClinicalTrials.gov Identifier: NCT02010034
• Other Study ID Numbers: STU 112010-159
• First Posted: Dec 12, 2013
• Last Update Posted: Feb 6, 2019
• Last Verified: Feb 1, 2019

• Keywords provided by Nandini Channabasappa, MD, Director, Intestinal Rehabilitation Program, Children's Medical Center Dallas: TPN; Liver Function; parenteral nutritional fat emulsions
• Additional relevant MeSH terms: Liver Diseases

Study Results

No Results Posted as of Feb 6, 2019